Scynexis (SCYX) EBITDA (2013 - 2026)
Scynexis' (SCYX) quarterly EBITDA came in at -$7.8 million in Q2 2026, up 18.68% on a YoY basis from -$6.6 million in Q2 2025, and up 54.1% quarter-over-quarter from -$16.9 million in Q1 2026.
Analysis
Scynexis (SCYX) EBITDA (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported EBITDA for 14 consecutive years, with -$7.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA rose 18.68% year-over-year to -$7.8 million; the trailing twelve-month figure through Jun 2026 stood at -$22.6 million (up 38.16% YoY), and the FY2025 full-year result was -$16.1 million, up 56.69% from the prior year.
- EBITDA grew to -$7.8 million in Q2 2026 per SCYX's latest filing, from -$16.9 million in the prior quarter.
- Across five years, EBITDA topped out at $116.5 million in Q2 2023 and bottomed at -$23.1 million in Q4 2023.
- Historically, EBITDA has averaged -$5.1 million across 5 years, with a median of -$9.8 million in 2023.
- The sharpest annual moves came in 2022 and 2023: EBITDA sank 1138.27% in 2022, then surged 635.99% in 2023.
- Over 5 years, EBITDA stood at -$22.5 million in 2022, then fell by 2.6% to -$23.1 million in 2023, then surged by 65.09% to -$8.1 million in 2024, then surged by 230.65% to $10.5 million in 2025, then sank by 173.9% to -$7.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$7.8 million, -$16.9 million, and $10.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -7.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.78 Mn |
| Mar 31, 2026 | -16.94 Mn |
| Dec 31, 2025 | 10.52 Mn |
| Sep 30, 2025 | -8.41 Mn |
| Jun 30, 2025 | -9.56 Mn |
| Mar 31, 2025 | -8.61 Mn |
| Dec 31, 2024 | -8.05 Mn |
| Sep 30, 2024 | -10.32 Mn |
| Jun 30, 2024 | -9.24 Mn |
| Mar 31, 2024 | -9.51 Mn |
| Dec 31, 2023 | -23.07 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | 116.51 Mn |
| Mar 31, 2023 | -10.68 Mn |
| Dec 31, 2022 | -22.48 Mn |
| Sep 30, 2022 | -21.80 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | -19.74 Mn |
| Dec 31, 2021 | -22.30 Mn |
| Sep 30, 2021 | -19.44 Mn |